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1. Introduction
In this chapter, we will discuss the interactions between a neurotransmitter that has been
heavily implicated in ADHD, dopamine, and a neurotransmitter just beginning to be inves‐
tigated, glutamate. We will examine the literature to reveal how current treatments for
ADHD affect these neurotransmitter levels in specific areas of the brain that are thought to
be dysfunctional in ADHD. Additionally, we will detail new data on dopamine and gluta‐
mate dysfunction utilizing approaches that are capable of accurately measuring levels of
these neurotransmitters in two separate rodent models of ADHD. Finally, we will speculate
on the role that the dopamine-glutamate interaction will play in the future neuropharmacol‐
ogy of ADHD and how measuring these neurotransmitter levels in rodent models of ADHD
may aid in furthering the future pharmacotherapy of ADHD.
Throughout the text, we will use ADHD (Attention-Deficit/Hyperactivity Disorder) without
reference to the DSM-IV type, unless a specific reference pertains to combined, inattentive or
hyperactive subtypes.
2. ADHD and the link to neurochemistry
When the Diagnostic and Statistical Manual of Mental Disorders (DSM-1) was first publish‐
ed in 1952, childhood psychiatric disorders were thought to be caused by environment and
referred to as ‘reactions’ [1]. It wasn’t until the DSM-2 was published in 1968 that ADHD
© 2013 Miller et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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began to be separated from general reactions and become its own diagnosis, referred to as
the ‘hyperkinetic reaction of childhood.’ This reaction was characterized by a short attention
span, hyperactivity, and restlessness [2], and in 1980, with the publication of the DSM-3, the
ADHD diagnosis became more specific and was described as ADD (attention-deficit disor‐
der) [3]; however, by this time, this disorder was already being treated with stimulant medi‐
cations, a treatment still used to this day.
Stimulant medications were initially discovered to treat hyperactivity in the early 1900s
when the psychiatrist Charles Bradley used amphetamines to treat children with headaches
caused by pneumoencephalography and found it improved their school performance, social
interactions and emotional responses. However, amphetamine as a treatment for ADHD
was ignored until years later due to a variety of reasons [4]. In the 1950s, researchers were
beginning to look for the underlying mechanisms causing behavioral problems and it was at
this time that Bradley’s discovery of amphetamine as a treatment for hyperactivity was un‐
covered and investigations into the mechanism of action of amphetamine began. The am‐
phetamine formulation Bradley used in his patients was called Benzedrine, a racemic
mixture of 50/50 d- and l-amphetamine, produced by the company Smith, Kline and French
[4]. Treatment with this medication in a variety of experimental paradigms reduced hyper‐
activity [5]; however, of particular note is a study published in 1976 showing decreased hy‐
peractivity when treated with amphetamine in rodents with dopamine depletion [6]. This
was the first time that hyperactivity was linked to dopamine, but far from the last.
2.1. Dopamine
Dopamine, classified as a catecholamine neurotransmitter, is produced in the cells of the
substantia nigra (SN, A9) and ventral tegmental area (VTA, A10) of the midbrain and project
to numerous brain regions, including the prefrontal cortex (PFC), striatum and nucleus ac‐
cumbens (NA, see Figure 1). Projections from the VTA to the NA are identified as the meso‐
limbic pathway, or the “reward pathway,” because these dopamine projections are involved
in rewarding behaviors, [7] firing when a reward is greater than expected or when a reward
is anticipated [8-10]. Projections from the SN to the striatum are referred to as the nigrostria‐
tal pathway and play a role in many aspects of motor control [11]. The mesocortical system
consists of dopaminergic projections from the VTA to the PFC, and it is implicated in many
cognitive functions including, but most certainly not limited to, attention and memory [11].
The mesocortical system will be the main focus in this chapter.
Dopamine is produced from tyrosine into 3,4-dihydroxyphenylalanine (DOPA) by the en‐
zyme tyrosine hydroxylase. DOPA is then made into dopamine via DOPA-decarboxylase.
Conversely, dopamine is broken down or converted by a number of mechanisms: 1) dopa‐
mine-β-hydroxylase converts dopamine into norepinephrine, 2) monoamine oxidase (MAO)
converts dopamine into 3,4-dihydroxyphenylacetic acid (DOPAC), and 3) catechol-o-methyl‐
transferase (COMT) catalyzes the formation of homovanillic acid (HVA). Dopamine-β -hy‐
droxylase only exists in norepinephrine neurons and thus will not be a focus here; however,
MAO exists on the outer mitochondrial membrane and is also thought to be in abundance
extracellularly, and COMT is mostly present extracellularly and plays a major role in regu‐
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lating dopamine neurotransmission, especially in the PFC [11]. The final and most impor‐
tant method in which dopamine is cleared from the synapse is via the dopamine transporter
(DAT). The DAT primarily exists on the presynaptic neuron and can transport dopamine ei‐
ther into or out of the neuron, dependent upon the concentration gradient. It has been dis‐
covered that the removal of dopamine from the synapse is predominantly performed by the
DAT and not metabolism or diffusion [12].
Figure 1. Modulatory dopaminergic neurons (blue) project to the dorsal striatum via the substantia nigra (SN, A9) and
the ventral striatum and prefrontal cortex (PFC) via the ventral tegmental area (VTA, A10) in the rodent brain. From
the striatum, inhibitory GABA neurons (green) extend to multiple regions including the thalamus, which has reciprocal
excitatory glutamate connections (red) to the striatum, as well as connections to the PFC. Prefrontal cortical efferent
excitatory glutamate neurons extend to the striatum, nucleus accumbens (NA), SN, as well as the VTA.
Intracellularly, dopamine is packaged into vesicles via the vesicular monoamine transporter
(VMAT-2). The release of dopamine from the vesicle is Ca2+ and Na+ dependent and occurs
when an action potential raises the Ca2+ levels in the presynaptic neuron, causing vesicles
stored with dopamine to bind to the cellular membrane and release their contents. The re‐
sulting synaptic dopamine is then able to bind to dopamine receptors on both the pre- and
postsynaptic neurons. These receptors are classified into two major categories: 1) D1-type re‐
ceptors, consisting of D1 and D5 and expressed postsynaptically, and 2) D2-type receptors ex‐
pressed both pre- and postsynaptically, consisting of D2 (short), D2 (long), D3 and D4.
Stimulation of D1-type receptors causes increased cAMP production (activating), whereas
stimulation of D2-type receptors causes inhibition of cAMP production (inhibiting). The ef‐
fects of these receptors give dopamine the classification of a modulatory neurotransmitter.
For a simplified PFC dopamine synapse diagram, see Figure 2.
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Figure 2. Dopaminergic and glutamatergic synapses in the PFC, simplified. Left: pre-synaptically, dopamine is trans‐
ported into vesicles, which release their contents upon increase of the Ca2+ concentration. Synaptic dopamine is then
able to stimulate dopamine receptors on both the pre- and postsynaptic neurons before it is cleared by the DAT or
metabolism. Right: presynaptically, glutamate is stored in vesicles and then released into the extracellular space. Syn‐
aptic glutamate is then able to stimulate glutamate receptors (here represented as the NMDA and mGluR) on both
the pre- and postsynaptic neurons before it is cleared by the EAAT located on nearby glial cells.
2.2. Glutamate
Recent clinical evidence has implicated glutamate in ADHD. Much of the initial evidence
stems from proton magnetic resonance spectroscopy studies of children and adults with
ADHD.  These  studies  have  shown  increased  levels  of  a  marker  for  glutamate  in  the
striatum and anterior cingulate cortex of the PFC [13-15]. Based on this evidence, new in‐
vestigations  into  glutamatergic  function  in  ADHD are  ongoing.  Glutamate  is  the  major
excitatory neurotransmitter  in the central  nervous system and must be tightly regulated
for proper neuronal signaling to occur [16]. Unlike dopamine, glutamate is in abundance
in  most  areas  of  the  brain.  Glutamate  projections  originating  in  the  PFC extend  to  the
striatum, NA, VTA and SN of the midbrain (see Figure 1). Glutamate is produced in the
nerve  terminals  of  these  projections  from two sources:  1)  the  Krebs  cycle  and 2)  gluta‐
mine produced and excreted into  the  extracellular  space  via  glial  cells.  Once produced,
glutamate  is  transported  into  vesicles  via  the  vesicular  glutamate  transporter  (VGLUT)
and when Ca2+ levels increase to cause an action potential, vesicles stored with glutamate
bind  to  the  cellular  membrane  and  release  their  contents.  Clearance  of  glutamate  after
this calcium-dependent release into the extracellular space is primarily performed by the
membrane-bound  glutamate  transporter,  called  the  excitatory  amino  acid  transporter
(EAAT),  located  on  the  presynaptic  neuron  and  to  the  greatest  extent  by  surrounding
glial  cells.  The glutamate is  primarily taken up by the EAATs located on the glial  cells
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and is converted by glutamine synthetase into glutamine and transported out of the glial
cell by system N transporter. The glutamine is then taken up by the system A transport‐
er on the presynaptic neuron to help replenish glutamate levels through the mitochondri‐
al  bound glutaminase [11].  Glutamate acts on synaptic glutamate receptors in the target
brain region, which are classified into two major types:  1) ionotropic,  which include the
NMDA,  AMPA  and  kainate  receptors  and  2)  metabotropic,  including  the  excitatory
mGluRs 1 and 5 (postsynaptic) and the inhibitory mGluRs 2, 3, 4, 6, 7, and 8 (presynap‐
tic). For a simplified PFC glutamate synapse diagram, see Figure 2.
2.3. Dopamine and glutamate interactions
A dysfunctional interaction between the dopamine and glutamate systems has been impli‐
cated in numerous neuropsychiatric disorders such as drug addiction, Alzheimer's disease,
schizophrenia, and ADHD. The brain regions most often linked to these disorders and the
dopamine-glutamate dysfunction are the PFC and striatum, as these regions both receive
heavy innervation from the dopaminergic SN/VTA and glutamate innervation from thala‐
mic relays and other glutamate rich regions, as described in the previous section.
Studies of signaling interactions between the dopaminergic and glutamatergic systems dem‐
onstrate that the NMDA receptor is crucial in activating dopamine neurons in the VTA/SN
[17, 18]. Also, it has been found that stimulation of the D2-class dopamine receptor is in‐
volved in the downstream inhibition of the NMDA receptor, weakening the excitatory re‐
sponse to those neurons [19]. Likewise, it was found that activation of D4 receptors
depressed AMPA receptor-mediated excitatory synaptic transmission in PFC pyramidal
neurons, which was accompanied by a D4-induced decrease of AMPA receptors at the syn‐
apse [20]. These results provide substantial evidence that the dopamine and glutamate neu‐
ronal systems work in tandem to create a balance of neurotransmission in these regions.
The hypodopaminergic theory of ADHD asserts that the hyperactive and inattentive behav‐
iors are caused by low levels of either tonic or phasic dopamine. If true, decreased dopamine
released in the striatum and PFC would then be expected to lead to more active NMDA and
AMPA receptors based on the studies mentioned above resulting in increased glutamatergic
output to the striatum and SN/VTA, as well as an increased glutamate signal to the PFC.
Glutamate coming into the SN/VTA would normally go on to release more dopamine [17];
however, in the ADHD brain, this feedback does not seem to occur.
2.4. Translational neuropharmacology of ADHD treatments
Investigations into the effects of stimulant action on the dopaminergic system have revealed
that these medications increase extracellular dopamine levels via numerous mechanisms.
First, amphetamine has been found to increase dopamine through calcium-independent
mechanisms such as increased release of dopamine and blocking the reuptake of dopamine
through the DAT [21, 22]. Methylphenidate (MPH), another stimulant medication common‐
ly used to treat ADHD, increases dopamine levels by inhibiting dopamine reuptake via the
DAT [23-29].
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The non-stimulant medication atomoxetine (ATX) is becoming increasingly popular as a
treatment for ADHD compared to the stimulant medications because it has lower abuse lia‐
bility. ATX has been found to increase levels of the catecholamines by selectively blocking
the norepinephrine transporter (NET), which is also able to clear dopamine [30-32] and, like
stimulants, is effective at lessoning the intensity of ADHD symptoms [33-36]. In vitro work
has shown that ATX acts as an NMDA receptor antagonist [37], providing preliminary evi‐
dence that current treatments for ADHD may have a direct effect on the glutamatergic sys‐
tem.
Using magnetic resonance spectroscopy, it was found that children treated with ATX, but
not MPH, had decreased levels of a marker for glutamate/glutamine in the PFC, though
MPH was able to decrease glutamate in the anterior cingulate cortex [38]. In the striatum,
both ATX and MPH decreased the glutamate/glutamine marker levels compared to controls
[13]. These results suggest that ATX may be regulating and activating prefrontal cortex neu‐
rons. However, another clinical study using a similar technique found that chronic long-act‐
ing MPH decreased glutamate levels in the PFC of children with ADHD [39]. Wiguna et al.
(2012) also discovered that MPH treatment resulted in an increase in the amount of and
functional state of the neurons in the PFC, supporting that the current ADHD stimulant
treatment MPH can activate PFC neurons as well. Further evidence of PFC activation comes
from a study of brain-derived neurotropic factor (BDNF), a marker for neuronal plasticity.
ATX was found to increase BDNF expression in the PFC; however, MPH had the opposite
effect and reduced BDNF expression in the PFC [40], though it must be noted that this study
was completed in naïve rodents and may explain why these results do not match those seen
in ADHD patients.
Many  second-line  and  experimental  treatments  for  ADHD  are  now  targeting  both  the
dopamine  and glutamate  systems.  Memantine  is  an  uncompetitive  NMDA receptor  an‐
tagonist [41] and has also been found to act as a D2 receptor agonist [42]. It has been ap‐
proved and used as  a  treatment  for  Alzheimer’s  disease;  however,  in  an 8  week open-
label  pilot  study  in  children  with  ADHD,  memantine  was  found  to  improve  ADHD
symptoms (Findling et  al,  2007).  Surman et  al.  (2011)  extended these  findings  to  adults
with  ADHD in a  separate  open-label  study lasting 12  weeks  and found similar  results,
with memantine improving ADHD symptoms and neuropsychological performance [43].
The MAO-B inhibitor (deprenyl),  which stops the degradation of dopamine and is  used
as a treatment in Parkinson’s disease,  was found to alleviate ADHD symptoms [44,  45].
These clinical data using glutamate and dopamine altering drugs provide strong links for
dysfunctional dopamine-glutamate interactions in ADHD, though the importance of this
dysfunction is still unknown. Based on these data, we believe it’s important to not over‐
look  the  possible  role  of  dysfunctional  dopamine-glutamate  interactions,  but  to  instead
focus on this relationship. Animal models of ADHD provide a unique opportunity to in‐
vestigate neurotransmitter system dysfunction as well  as to develop novel ways to treat
ADHD targeting  these  systems.  We will  next  highlight  two separate  models  of  ADHD
and how they are implicating both dopamine and glutamate dysfunction in ADHD.
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2.5. Animal models of ADHD: Hypotheses
The spontaneously hypertensive rat
The spontaneously hypertensive rat (SHR) has been used as an animal model for ADHD
combined type since the 1970’s because of its sustained attention deficits [46], motor im‐
pulsiveness  [47-49],  and hyperactivity  [46]  with  the  hyperactivity  absent  in  novel  situa‐
tions [50]. Currently, there exists conflicting data on dopamine release and uptake levels
in  the  brain  areas  thought  to  be  involved  in  the  pathophysiology  of  ADHD,  including
the PFC [51]. Our lab has previously reported enhanced dopamine uptake in the ventral
striatum and nucleus accumbens core of the SHR [52];  however,  investigations into PFC
dopamine regulation are still  not  clear.  The PFC of  the SHR has been reported to have
decreased dopamine uptake [53],  yet a study found no differences in the levels of DAT,
tyrosine hydroxylase, D1,  D2,  D3,  D5  receptors, and dopamine-β-hydroxylase between the
SHR and its progenitor strain, the Wistar Kyoto (WKY), in the PFC. Regional differences
in the D4  receptors in the PFC were found, providing evidence that the SHR’s D4  levels
are  lower  than those  of  the  WKY [54].  Further,  it  was  found that  PFC AMPA receptor
activity was increased in the SHR [55] and inhibitory dopaminergic activity was found to
be  decreased while  noradrenergic  activity  increased in  the  SHR [56].  These  findings  all
convey a message that dopamine regulation is dysfunctional in the PFC of the SHR mod‐
el of ADHD; however, direct observation of in vivo dopamine dynamics in the separate
PFC sub-regions (cingulate, prelimbic, and infralimbic) of the SHR have not yet been ac‐
curately defined.
The dopamine receptor D4 knockout mouse
The correlation between ADHD and the 7-repeat polymorphism in the dopamine D4 recep‐
tor (DRD4.7) is supported by neuroanatomical, neurochemical, molecular genetics and phar‐
macological studies [57-60]. Recently, the DRD4.7 was identified as having the most
significant genetic relationship to ADHD in pooled family and case-controlled studies [61].
Clinical studies in adolescents report that ADHD patients with the DRD4.7 have thinner
frontal cortical structures in comparison to age matched controls [62]. The highest concen‐
tration of DRD4s is in the frontal cortex, an area implicated in the pathophysiology of
ADHD using neuroimaging and neuropsychological evaluation of ADHD patients [63-66].
There is evidence that changes in DRD4 expression can affect glutamate levels in the stria‐
tum of DRD4-/- mice [67]. Previous studies show that DRD4-/- mice are supersensitive to etha‐
nol, cocaine and methamphetamine [68]; have enhanced reactivity to unconditioned fear
[69]; reduced exploration of novel stimuli [70]; and hypersensitivity to amphetamine [71]. In
the cortex, hyperexcitability has been demonstrated in DRD4-/- mice using immunohisto‐
chemical, electrophysiological, pharmacological and ultrastructural methods, indicating that
DRD4 activation has an inhibitory influence on glutamate neurons in the frontal cortex [72].
At this time, no direct studies of in vivo glutamate have been investigated in the intact PFC
of the DRD4-/- mouse. Therefore, in vivo measures of glutamatergic modulation in the PFC
may correlate changes in glutamate neurotransmission to the expression levels of the DRD4
and understanding the physiological role of the DRD4 may elucidate the importance of dop‐
amine and glutamate interactions in the PFC.
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Measuring neurotransmitters in these rodent models of ADHD
Recent studies point to the importance of a dysfunctional relationship between dopaminer‐
gic and glutamatergic neurotransmission in ADHD, therefore new investigations into this
relationship are necessary to improve our understanding and may lead to improved thera‐
peutics for ADHD. Based on our development of novel and revolutionary methods of meas‐
uring dopamine and glutamate in vivo, we realize we are in a unique position to test our
hypotheses that dopamine and glutamate regulation play a major role in the pathophysiolo‐
gy of ADHD. The development of carbon fiber microelectrodes and glutamate oxidase-coat‐
ed microelectrode arrays (MEAs) provide improved spatial resolution, sub-second temporal
resolution, and low limits of detection (<10 nM for dopamine [52], <0.2 μM for glutamate
[73]) over conventional techniques used in the past, such as microdialysis. The smaller size
of these probes and decreased damage to tissue compared to microdialysis probes allows for
the in vivo characterization of dopamine and glutamate signaling closer to the synapse. Us‐
ing these technologies, we were able to explore if dysfunction in dopamine and glutamate
neurotransmission occur in the PFC of the SHR and DRD4 models of ADHD. The studies
described here could potentially lead to the development of novel therapies for ADHD,
which will be discussed in detail later.
2.6. Neurotransmitter recording techniques: Methods
High-speed chronoamperometric recordings of dopamine release and uptake in the PFC
of the SHR
Male, 8-10 weeks old, inbred spontaneously hypertensive rats (SHR, average 225 g, average
PND 60), inbred Wistar Kyoto rats (WKY, average 210 g, average PND 61), and outbred
Sprague Dawley rats (SD, average 289 g, average PND 69) were obtained from Charles River
Laboratories (NCrl), Wilmington, Massachusetts. Animals were given access to food and
water ad libitum and housed in a 12 hour light/dark cycle. Protocols for animal use were
approved by the Institutional Animal Care and Use Committee, which is Association for As‐
sessment and Accreditation of Laboratory Animal Care International approved. All proce‐
dures were carried out in accordance with the National Institutes of Health Guide for Care
and Use of Laboratory Animals and all efforts were made to minimize animal suffering and
to reduce the number of animals used.
High-speed chronoamperometric measurements (1 Hz sampling rate, 200 ms total) were
performed using the FAST16mkII recording system (Fast Analytical Sensing Technology,
Quanteon, LLC, Nicholasville, Kentucky) as previously described [52, 74]. Single carbon fi‐
ber electrodes (SF1A; 30 μm outer diameter × 150 μm length; Quanteon, LLC, Nicholasville,
Kentucky) were coated with Nafion® (5% solution, 1–3 coats at 180oC, Aldrich Chemical Co.,
Milwaukee, Wisconsin) prior to an in vitro calibration used to determine selectivity, limit of
detection, and sensitivity before use in vivo: average selectivity for all microelectrodes used
in these experiments was 1877 ± 664 μM for dopamine vs. ascorbic acid; average limit of de‐
tection for the measurement of dopamine was 0.028 ± 0.008 μM (S/N of 3); average slope for
the electrodes was -0.492 ± 0.111 nA/μM dopamine. After calibration, miniature Ag/AgCl
reference electrodes were prepared as previously described [74]. The carbon fiber microelec‐
Attention Deficit Hyperactivity Disorder in Children and Adolescents116
trode was affixed to a micropipette (10 μm inner diameter) which was positioned approxi‐
mately 200 μm from the carbon fiber electrode tip using sticky wax (Kerr USA, Romulus,
Michigan).
Rats were anesthetized intraperitonealy (i.p.) using a 25% urethane solution (1.25 g/kg) and
placed in a stereotaxic frame (David Kopf Instruments, Tujunga, California). A circulating
heating pad (Gaymar Industries, Inc., Orchard Park, New York) was used to maintain body
temperature. The skull was removed bilaterally for recordings in the PFC (AP +3.2, ML ±1.0,
DV -2 to -6 in 0.5 mm increments) [75]. A small hole remote from the site of surgery was
drilled for placement of the miniature Ag/AgCl reference electrode. Prior to experimenta‐
tion, the micropipette was filled with filtered isotonic KCl (120 mM KCl, 29 mM NaCl, 2.5
mM CaCl2•2H2O) solution (pH 7.2-7.4) using a 4 inch filling needle (Cadence Inc., Staunton,
Virginia) and a 5 ml syringe. Experiments were then initiated with the insertion of the mi‐
cropipette/microelectrode assembly into a stereotactically selected region of the left or right
hemisphere’s PFC. After a 30-45 minute baseline, the effect of a single local application of
KCl on dopamine release was determined [52]. The KCl solution was locally applied by
pressure ejection (5–25 psi for 0.5 seconds) and the single application of a set volume of KCl
(75–125 nl) was delivered to each sub-region, measured by determining the amount of fluid
ejected from the micropipette using a dissection microscope fitted with an eyepiece reticule
that was calibrated so that 1 mm of movement was equivalent to 25 nl of fluid ejected [76,
77]. If the volume was determined to be greater or less than 75-100 nl, then that data point
was excluded. After the KCl studies, the micropipette/microelectrode assembly was filled
with filtered isotonic 200 μM dopamine solution containing 100 μM ascorbic acid (an anti-
oxidant) in 0.9% saline (pH 7.2-7.4). The micropipette/microelectrode assembly was inserted
stereotactically into the animal’s contralateral PFC. Again, a stable baseline was achieved be‐
fore the dopamine solution was locally applied by pressure ejection (10-30 psi for 0.5-10 s) to
achieve a maximum amplitude between the range of 0.5 to 1 μM dopamine. The maximum
concentration of the dopamine in the extracellular space was measured by subtracting the
apex of the recorded peak from the baseline recorded prior to the ejection. If the peak ampli‐
tude was greater or less than 0.5 to 1 μM dopamine, then that data point was excluded.
Brains were removed and processed (frozen) for histological evaluation of microelectrode
recording tracks. Only data from histologically confirmed placements of microelectrodes in‐
to the PFC were used for final data analysis. Based on histological analyses, no animals were
excluded due to microelectrode placement errors.
Collected data were processed using a custom Matlab®-based analysis package. For KCl-
evoked DA release, maximum amplitude of the evoked dopamine peak was used. The vol‐
ume of KCl applied was kept constant across depths and strains (75–125 nl). For dopamine
uptake the time to 80% decay of the dopamine signal (T80) was examined. dopamine signals
were amplitude matched (ranging from 0.5 to 1 μM dopamine) to ensure accurate measure‐
ment of dopamine uptake kinetics [52, 74]. Outliers were excluded via the Grubb’s test be‐
fore averaging if the conditions for homogeneity of variance were met. To compare
dopamine dynamics in the separate PFC subregions, one-way ANOVAs followed by Bonfer‐
roni post-hoc comparisons were used. Significance was set at p<0.05 (GraphPad Prism 5.0).
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Urethane, dopamine, ascorbic acid, sodium chloride, potassium chloride, calcium chloride
and Nafion® were obtained from Sigma (St. Louis, MO). Carbon fiber microelectrodes
(SF1A’s) were fabricated by the Center for Microelectrode Technology.
High-speed amperometric recordings of glutamate levels in the PFC of the DRD4 knock‐
out mouse
Male mice (5-7 months; ~32 g) descended from the original F2 hybrid of mice with a truncat‐
ed and non-expressing DRD4 gene (DRD4-/-; 129/SvEv × C57BL/6J) were derived by back‐
crossing the DRD4+/- mouse line for 20 generations [68]. In all experiments, the DRD4-/- mice
(n=5-8) and DRD4+/- (n=5-9) were compared to litter-matched DRD4+/+ (n=5-8) animals. Mice
were group-housed (2-4 per cage) with unlimited access to food and water. Mice were main‐
tained on a twelve hour light/dark cycle. Protocols for animal use were approved by the In‐
stitutional Animal Care and Use Committee (IACUC), which is Association for Assessment
and Accreditation of Laboratory Animal Care International approved, and all procedures
were carried out in accordance with the National Institutes of Health Guide for Care and
Use of Laboratory Animals.
Ceramic-based microelectrode arrays (MEA) that contained 4 platinum (Pt) recording surfa‐
ces (sites 1-4) in an S2 configuration (two sets of side-by-side recording sites) were prepared
to selectively measure glutamate. The electrodes were fabricated for in vivo recordings us‐
ing published methods [73, 78, 79]. All 4 sites were electroplated with meta-phenylene dia‐
mine (mPD) by applying a potential of +0.5 V to the Pt sites vs. a silver/silver chloride (Ag/
AgCl) reference electrode (Bioanalytical Systems, RE-5) in a deoxygenated 0.05 M phosphate
buffered saline (PBS; pH 7.1-7.4) with 5 mM mPD. The mPD forms a size-exclusion layer
over the sites, blocking dopamine, ascorbic acid (AA), DOPAC, and other electroactive com‐
pounds. Pt sites 1 and 2 were coated with glutamate oxidase (Glu-Ox) within an inert pro‐
tein matrix of bovine serum albumin (BSA) and gluteraldehyde, enabling these sites to
detect glutamate levels on a sub-second timescale with low levels of detection (0.2 μM). Sites
3 and 4 were coated with only BSA and gluteraldehyde [80, 81]. In the presence of Glu-Ox,
glutamate is broken down into α-ketoglutarate and peroxide (H2O2). The H2O2 is small
enough to traverse the mPD layer and is readily oxidized and recorded as current using the
FAST-16 equipment (Fast Analytical Sensor Technology (FAST); Quanteon L.L.C., Nicholas‐
ville, KY). For calibration details, see [73, 78]. From the calibration, average values for slope
were -7.7 ± 4.8 pA/μM, selectivity 214 ± 64 to 1 and LOD 0.59 ± 0.06 μM (n=26 electrodes; 51
glutamate recording sites). After the MEA was calibrated; a single barrel glass capillary with
filament (1.0 x 0.58 mm2, 6”, A-M Systems, Inc., Everett, WA) was pulled using a Kopf Pip‐
ette Puller (David Kopf Instruments, Tujunga, CA) and bumped against a glass rod so that
the inner diameter of the micropipette was 10-12 μm. The tip of the micropipette was placed
between the 4 Pt recording sites, approximately 50-80 μm away from the electrode surface
and secured using Sticky Wax (Kerr Manufacturing Co, Detroit, Michigan).
Mice were anesthetized using i.p. injections of 10% urethane solution (1.25 g/kg) and placed
in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) fitted with a Cunningham™
Mouse and Neonatal Rat Adaptor (Stoelting Co., Wood Dale, IL). A circulating heating pad
(Gaymar Industries, Inc., Orchard Park, NY) was used to maintain body temperature. The
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skull overlying the PFC was removed bilaterally. The MEA–micropipette assembly was
positioned in the brain according to the following stereotaxic coordinates where all anterior-
posterior (AP) measures were from bregma, medial-lateral (ML) measures were from mid‐
line and dorsal-ventral (DV) measures were from dura: AP: +2 mm, ML: ±1 mm, DV: -1.8 to
2.6 mm at an angle of 8 degrees according to the atlas of The Mouse Brain in Stereotaxic Co‐
ordinates [82]. An additional hole, remote from the surgery site, was opened for a Ag/AgCl
reference electrode. Prior to placement of the MEA-pipette assembly, the micropipette was
filled with isotonic 125 μM glutamate (125 μM L-glutamate in 0.9% physiological saline;
pH= 7.2-7.4) using a combination of a 1 ml syringe filled with glutamate solution, a 0.22 μm
sterile syringe filter (Costar Corporation), and a 4” stainless steel pulled needle (30 gauge,
beveled tip; Popper and Son, Inc., NY). A potential of +0.7 V was applied versus a miniature
Ag/AgCl reference electrode and the data were displayed at a frequency of 2 Hz. Upon ster‐
eotaxic placement of the MEA-micropipette assembly, 10-20 minutes of baseline data were
acquired. Extracellular levels of glutamate were measured by averaging 30 seconds of base‐
line recordings prior to application of glutamate or KCl. Then, a 125 μM glutamate solution
was locally applied via pressure ejection using a Picospritzer II connected to the open end of
the micropipette by plastic tubing (Parker Hannifin Corp., General Valve Corporation).
Pressure was applied at 5-25 psi for 1 second in all of the experiments. Glutamate was ap‐
plied every 30-60 seconds for a total of 10 recordings. The MEA was then lowered in 350 μm
increments. Baseline recordings were acquired for 5-10 minutes and the recordings were re‐
peated. Parameters from three of the ten signals ranging from 10-30 μM in amplitude were
averaged for each Pt electrode site at each depth. Signals were analyzed for time required to
rise to maximum amplitude (rise time), time for 80% of the signal to decay from maximum
amplitude (T80), and the rate of uptake. The uptake rate was calculated by multiplying the
first order rate constant (k-1, seconds-1) by the maximum amplitude (uptake rate = μM/s) [81].
All data from local applications of glutamate from a given site were pooled into a single
point. Amplitude-matched signals were compared to assess genotypic differences in the
rates of clearance of exogenous glutamate [83]. Brains were removed and processed for his‐
tological evaluation of microelectrode recording tracts. Only data from histologically con‐
firmed placements of microelectrodes within the PFC were used for final data analysis.
Data from the side-by-side recordings were averaged and used as a single data point. If only
one microelectrode site provided usable data, then the recordings were reported as from
that site. Very few data points were omitted in this study due to outlier status, with excep‐
tion for constraints on amplitude-matching. To determine statistical significance (p<0.05),
processed data were analyzed using a one-way ANOVA with Tukey’s post-hoc compari‐
sons across all genotypes (Graphpad Prism 4.0). Urethane, L-glutamate, dopamine, ascorbic
acid, and 1,3-phenylenediamine dihydrochloride were obtained from Sigma-Alderich, St.
Louis MO). Microelectrode arrays were provided by Quanteon L.L.C. (Nicholasville, KY).
2.7. Dopamine dysfunction in the PFC of the SHR model of ADHD: Results
High-speed chronoamperometry coupled with carbon fiber microelectrodes was used to
evaluate KCl-evoked dopamine release because of its capability to record dopamine release
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within sub-regions of the striatum and the NA [52, 74] using a local application of 75-125 nl
KCl in 500 μm increments. To examine potential differences in evoked dopamine release in
the separate sub-regions of the PFC between the outbred SD, the WKY progenitor, and the
SHR model of ADHD, one-way ANOVAs were used. No significant differences were found
between strains (cingulate cortex, p=0.1295; prelimbic cortex, p=0.1998; infralimbic cortex,
p=0.1050). These data suggests that the cingulate, prelimbic and infralimbic regions in all
three strains have a similar capacity to release dopamine during an action potential event.
It’s important to note that in both the SD and SHR strains, dopamine peak amplitudes in‐
creased as the microelectrode was moved ventrally; however, the WKY strain displayed the
opposite effect. See Figure 3. Note that all dopamine signals were indicative of the detection
of dopamine and/or norepinephrine based on the reduction/oxidation rations of the signals
that averaged ~0.8-1.0 for all recordings.
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Figure 3. No differences were observed between the outbred SD control strain, the WKY progenitor strain, and the
SHR model of ADHD in the KCl-evoked dopamine peak amplitudes following a local application of KCl in any of the
prefrontal cortical sub-regions. Values represent the mean ± SEM.
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Figure 4. The SHR model of ADHD and the outbred SD control strain exhibited significantly faster dopamine uptake
than the WKY strain in the cingulate cortex (*p<0.05, ***p<0.001). No dopamine uptake differences were observed in
the prelimbic cortex; however, the SHR exhibited significantly faster dopamine uptake in the infralimbic cortex com‐
pared to both the SD control and WKY strain (*p<0.05, **p<0.01). Values represent the mean ± SEM.
To examine differences in dopamine uptake in the separate prefrontal cortical sub-regions,
we used local applications of dopamine to directly observe the functional properties of the
dopamine and norepinephrine transporters. One-way ANOVAs followed by Bonferroni
post-hoc comparisons were used in each sub-region. It was discovered that the SHR model
of ADHD (p<0.05) and the outbred SD control strain (p<0.001) displayed significantly faster
dopamine uptake compared to the WKY strain in the cingulate cortex (F(2,23)=11.11). The
average dopamine uptake times in the cingulate cortex were: SD, 30.8 ± 2 seconds; WKY,
79.1 ± 10 seconds; and SHR, 44.8 ± 3 seconds. No dopamine uptake differences were ob‐
served in the prelimbic cortex (p=0.9605); however, the SHR exhibited significantly faster
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dopamine uptake compared to both the SD control (p<0.01) and the WKY strain (p<0.05) in
the infralimbic cortex (F(2,28)=6.53). The average dopamine uptake times in the infralimbic
cortex were: SD, 61.6 ± 8 seconds; WKY, 49.8 ± 11 seconds; and SHR, 18 ± 4 seconds. These
data reveal that the dopamine and norepinephrine transporters clear dopamine faster in the
SHR in the cingulate and infralimbic cortices compared to control, but not the prelimbic cor‐
tex. It’s important to note that as the microelectrode was moved ventrally in the control SD
strain, the dopamine uptake became slower; however, in the WKY and SHR strains, dopa‐
mine uptake became faster as the electrode moved ventrally.
2.8. Glutamate dysfunction in the PFC of the DRD4-/-
mouse model of ADHD: Results
In  order  to  evaluate  the  effect  of  DRD4s  on  extracellular  levels  of  glutamate,  we  com‐
pared  extracellular  glutamate  levels  across  genotypes  in  the  PFC.  Extracellular  resting
levels  of  glutamate  were  higher  by  approximately  73%  in  the  PFC  of  DRD4-/-  mice  in
comparison to their  DRD4+/+  littermates (DRD4+/+:  1.4 ± 0.2 μM, n=8,  signals=22;  DRD4+/-:
1.9 ± 0.3 μM, n=8, signals=23; DRD4-/-: 2.5 ± 0.3 μM, n=8, signals=24; p<0.05, see Figure 5).
A depth analysis showed that DRD4+/+  mice maintained similar extracellular resting glu‐
tamate levels across depths (1.4 ± 0.3 μM), while DRD4-/- mice tended to have higher lev‐
els  throughout  all  areas.  The  most  profound  difference  was  the  stepwise  increase  in
extracellular  glutamate  levels  in  the  cingulate  cortex  with  a  significant  difference  ob‐
served between the DRD4+/+  and DRD4-/-  mice (DRD4+/+:  1.4 ± 0.3 μM, n=8; DRD4+/-:  2.0 ±
0.6 μM, n=7 ; DRD4-/-: 3.0 ± 0.7 μM, n=8; Student’s t-test: p<0.05; see Figure 5) These data
indicate that the loss of DRD4s results in increased extracellular resting glutamate levels
in the PFC, most dramatically in the cingulate cortex.
The in vivo activity of glutamate uptake was examined with a high degree of temporal and
spatial resolution by locally applying exogenous glutamate to the extracellular space of the
brain and measuring the presence and successive clearance kinetics. Resulting data provid‐
ed kinetic measures that allowed us to evaluate the efficiency of exogenous glutamate re‐
moval from the extracellular space within the 3 different brain areas of the medial PFC.
Statistical comparisons were made on amplitude-matched data in order to make sure that
variations in maximum amplitude would not contribute to changes in rise time, uptake rate
and T80. Average maximum amplitudes were 15.39 ± 1.30 μM (n=8; signals= 21), 13.62 ± 0.78
μM (n=9; signals =25) and 13.93 ± 0.91 μM (n=8; signals = 21) in the DRD4+/+, DRD4+/- and
DRD4-/-, respectively. Uptake rates within the PFC were similar across genotypes (DRD4+/+:
4.85 ± 0.69 μM, n=8; DRD4+/-: 4.82 ± 0.46 μM, n=9; DRD4-/-: 5.28 ± 0.74 μM, n=8; see Figure 6).
The time it took for 80% of the signal to decay (T80) was significantly longer in DRD4-/- mice
than wildtype (DRD4+/+: 2.50 ± 0.16 μM, n=8; DRD4+/-: 2.84 ± 0.12 μM, n=9; DRD4-/-: 3.00 ± 0.14
μM, n=8; p<0.05) with the most profound changes occurring in the prelimbic area (p<0.05).
These kinetic measures of glutamate clearance in the PFC indicate that the DRD4 may play
an important role in glutamate clearance.
Attention Deficit Hyperactivity Disorder in Children and Adolescents122
Figure 5. Extracellular resting levels of glutamate in the PFC. The top bar graph shows increased extracellular levels of
glutamate in the PFC of DRD4-/- in comparison to DRD4+/+ mice (*p<0.05). The bottom graph depicts extracellular rest‐
ing glutamate levels broken down by depth in the PFC. The numbers on the x-axis represent the depth of the micro‐
electrode (1.8, 2.15 and 2.5 mm) and indicate the cingulate cortex, the prelimbic area and the infralimbic area;
respectively. Values represent the mean ± SEM.
2.9. Implications of dysfunctional neurotransmitter systems
The SHR and dopaminergic PFC dysfunction
Based on current stimulant treatments for ADHD that target the dopaminergic system, such
as MPH, the hypofunctional catecholamine theory has evolved and states that behaviors
seen with ADHD are caused by decreased levels of catecholamines in the brain regions asso‐
ciated with attention and reward processing [84] including the striatum and PFC. In the
spontaneously hypertensive rat (SHR) model of ADHD, there have been conflicting reports
of dopamine levels in the striatum and PFC; however, the techniques used varied with each
study. Some studies revealed a hypodopaminergic tone [85, 86], while others found no dif‐
ference in dopamine levels [87, 88]. Microdialysis measures of dopamine levels in the SHR
are at most unreliable and poorly reflect concentrations of dopamine near the synapse due
to the limited spatial resolution (>1 mm), slow sampling rates (1-20 min), and significant
damage to the surrounding tissue [89-91]. Based on this premise, it is necessary that a tech‐
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nique with increased spatial and temporal resolution over microdialysis, such as carbon fi‐
ber microelectrodes coupled to high-speed chronoamperometric recordings, be used to
measure dopamine dynamics in this popular animal model [92].
Figure 6. Glutamate clearance in the PFC. The top bar graphs represent changes in glutamate clearance in the PFC as
a function of DRD4 expression for amplitude-matched signals. The T80 is significantly longer in DRD4-/- mice in com‐
parison to DRD4+/+ (*p<0.05). A depth profile of the T80 values (bottom) indicate that the most significant difference
was in the prelimbic area of the PFC (2.15 mm) in the DRD4-/-. Values represent the mean ± SEM.
Recent data from our lab using carbon fiber microelectrodes with high-speed chronoamper‐
ometry have shown decreased potassium-evoked dopamine signals in the dorsal striatum of
the SHR model of ADHD compared to the WKY, as well as faster dopamine uptake in the
ventral striatum and NA core in the SHR compared to both the SD and WKY controls [52].
Previous investigations have implicated the dopamine transporter (DAT) in the dopamine
dysfunction of the SHR model of ADHD [93-98] and our data revealing differences in dopa‐
mine regulation in the striatum can be attributed to increased activity of the DAT in the
striatum of the SHR. It is reasonable to assume that if the striatum has increased DAT activi‐
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ty, it’s likely that similar dopamine dysfunction exists in the PFC of the SHR. It’s important
to clarify that the norepinephrine transporter (NET) is present in certain regions of the PFC
in much greater concentrations than the DAT and dopamine uptake in the PFC is thought to
be preferentially due to the NET instead of the DAT [99], so investigations into the mecha‐
nism of dopamine clearance in the PFC of the SHR should be examined in the future.
Using similar volumes of a potassium solution, evoked overflow of catecholamine nerve ter‐
minals surrounding the tip of the carbon fiber microeletrode was used to attempt to locate
differences in vesicular dopamine storage in the different PFC sub-regions. Upon stimula‐
tion, no differences were observed between the inbred SHR model of ADHD, the inbred
progenitor WKY and the outbred SD control strains. The lack of differences signifies to us
that the separate PFC sub-regions all have the same capacity to store and release dopamine
and/or norepinephrine in these strains. MAO and VMAT, both implicated in ADHD, can
then be considered to be functional in the PFC of the SHR model of ADHD and drugs tar‐
geting these proteins, such as deprenyl, may not be useful in this model.
Though no differences were observed in the KCl-evoked dopamine signals, there were sig‐
nificant differences in the length of time required to clear exogenous dopamine applications
between the SHR and control strains. Similar maximum dopamine amplitudes were ach‐
ieved by applying various volumes of an exogenous dopamine solution in order to evaluate
the uptake kinetics of the signals. The DAT is electrogenic and depolarization causes the
DAT to change from the basal state [100-104] and in order to test the full uptake capabilities
of the transporters, including both the DAT and NET, it was necessary to study the trans‐
porters in their more natural state using local applications of dopamine. Utilizing this ap‐
proach, it was discovered that the SHR displayed faster uptake in the cingulate and
infralimbic cortices compared to the WKY strain, but not the prelimbic cortex. The SHR
model of ADHD was also discovered to have faster dopamine uptake compared to the SD
strain in the infralimbic cortex. These results are significant because the cingulate cortex is
involved with learning and memory, playing a vital role in the Papez circuit and the cortical
control of emotions in humans [105]. These data further demonstrate that there exists a neu‐
rochemical dysfunction in a region important for linking behavioral outcomes to motivation
[106, 107] in the SHR. Also, the infralimbic cortex in rodents is known to be involved with
attention to stimulus features, task contingencies, and attentional set-shifting [108] – all be‐
haviors known to be affected in individuals with ADHD [109-111].
The SHR has previously been found to have dysfunctional dopamine dynamics in the stria‐
tum and NA core [52], but here we also show evidence for faster dopamine uptake in the
cingulate and infralimbic cortices of the medial PFC. These regions are heavily implicated in
ADHD [66, 112, 113] and these data give further evidence for use of the SHR as a model of
ADHD. Therapeutics targeting this dysfunction may prove to be useful in the SHR. Howev‐
er, MPH, a DAT blocker, has been investigated and found to not be useful in this model be‐
cause instead of calming these animals as it does in humans, it increased locomotion in
clinically relevant doses [46, 47, 114]. This signifies to us that targeting the NET instead of
the DAT, such as with the use of ATX, may provide a more useful option of targeting PFC
dopamine dysfunction in the SHR model of ADHD.
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The DRD4 and glutamatergic PFC dysfunction
The 7-repeat polymorphism of the DRD4 has been implicated in ADHD. Little is known
about the neurochemical effects of the DRD4 and thus the DRD4.7. While the DRD4-/- mouse
is not an exact model for ADHD, it does provide insight to the neurochemistry of DRD4 sig‐
naling. In these studies we used in vivo amperometry coupled to a glutamate-selective MEA
to measure extracellular levels of glutamate and glutamate clearance in the PFC of DRD4+/+,
DRD4+/- and DRD4-/- mice. We measured a significant increase in extracellular resting levels
of glutamate, most prevalent in the cingulate cortex of the medial PFC. We also discovered
increased glutamate uptake times that were seen primarily in the prelimbic area. These data
support the hypothesis that DRD4 signaling is actively involved in regulating glutamate
neurotransmission in the PFC.
We found that lack of DRD4 expression resulted in increased extracellular resting levels
of glutamate in the PFC. We are unaware of any extracellular glutamate levels reported
from  the  PFC  of  anesthetized  C57BL\6  mice.  Using  similar  technology,  Hascup  et  al.
(2007) found extracellular levels of glutamate in the PFC of awake, freely-moving C57Bl
\6 mice to be 3.3 ± 0.1 μM [81]. In this study, we reported approximately 60% of the ex‐
tracellular  levels  recorded from these  prior  studies  in  awake  animals  (1.42  ±  0.19  μM).
Urethane  anesthesia  has  been  documented  to  reduce  extracellular  glutamate  levels  by
58-80% in rats and may be contributing to the lower levels of glutamate measured here
[81, 115].  The relative contributions of metabolic and neuronal pools of glutamate to ex‐
tracellular levels of glutamate and the role of D4 receptors in astrocytic regulation of glu‐
tamate  still  requires  investigation.  Consequences  of  increased  extracellular  levels  of
glutamate in  the PFC would cause alterations in  signaling due to  increased stimulation
of  glutamate receptors  on astrocytes  and presynaptic  and postsynaptic  neurons.  Further
studies  are  required  to  test  these  potential  changes.  There  is  also  indication  that  the
DRD4 is localized to GABA containing interneurons in the PFC [116, 117]. Lack of inhibi‐
tion resulting from loss  of  expression of  the  DRD4 could result  in  decreased release  of
GABA. This loss of inhibition could also contribute to increased tonic levels of glutamate
in the PFC.
Loss of DRD4 resulted in approximately a 20% increase in clearance times in DRD4-/- mice.
The mechanism of the increased clearance time is unknown, but the capacity of this tissue to
clear similar amounts of exogenous glutamate was not significantly altered in the DRD4-/-
mice, suggesting that transporter expression was unchanged. It is not known whether the
measured effects on uptake rate were a direct or indirect effect of DRD4 signaling loss. In all
areas of the brain, 80-90% of glutamate transporters are located on astrocytes [16]. Increased
activation of metabotropic glutamate receptors (mGluRs) on astrocytes could potentially af‐
fect glutamate clearance in this case, depending on the affinity for glutamate by the mGluRs
on astrocytes [118]. Interestingly, there have been reports of the presence of dopamine D2-
receptors on the astrocytes in the PFC [119]. Prior microdialysis data suggests that extracel‐
lular dopamine content and KCl-evoked release of dopamine are lower in the striatum and
NAc of DRD4-/- mice [120]. Alterations in dopamine neurotransmission in the PFC of these
mice may elucidate a special role for the D2 receptor on astrocytes in regulation of dopa‐
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mine and glutamate interactions in DRD4-/- mice in PFC neurotransmission. Dopamine neu‐
rotransmission studies have not been done in these mice, but changes in whole tissue levels
of dopamine and dopamine metabolites do not indicate any changes [72].
In multiple publications, the DRD4 has been indicated as having an important role in the
cortico-striatal-thalamic loop. Previously, we measured increased extracellular glutamate
and slower clearance of glutamate in the striatum, indicating DRD4 regulation in the corti‐
costriatal projections [67]. In these experiments, we measured increased extracellular gluta‐
mate levels and slower glutamate clearance in the PFC, representing alterations in
glutamatergic projections that primarily originate in the thalamus. Mrzljak et al. (1996) al‐
luded that the DRD4s role in pallido-thalamic pathways may be as a regulator of GABA re‐
lease [117]. By blocking these receptors, GABA release would be weakened and result in
enhanced excitatory pathways beginning in the thalamus. This presents a feed forward sit‐
uation in which lack of inhibitory modulation of the excitatory pathways of the cortico-stria‐
tal-thalamic loop results in increased levels of glutamate in the PFC and the striatum.
Although measures of GABA in the pallido-thalamic and striatopallidal projections are nec‐
essary, our data continues to support the importance of the DRD4 in the cortico-striatal-tha‐
lamic loop, specifically in the regulation of tonic glutamate.
Region specific changes may be due to the concentration of DRD4s and cell types to which
they are localized. In a study where bacterial artificial chromosomes expressed enhanced
green florescent protein under the transcriptional control of the DRD4, DRD4 localization
was found to be high in the orbital, prelimbic, cingulate and rostral agranular potions of the
prefrontal cortex [116]. Our study found changes in the cingulate and prelimbic areas, but
not the infralimbic area. Localization of DRD4s to interneurons vs. pyramidal neurons may
be helpful in elucidating a relationship between altered extracellular glutamate levels in the
cingulate cortex in comparison to altered clearance times in the prelimbic area. One caveat
of transgenic mice is that compensatory effects may be contributing to the neurochemical ef‐
fects that we measured. While compensatory effects in the PFC have not been evaluated, al‐
terations in dopamine D1 receptor and NMDA receptor expression were reported in the
striatum, nucleus accumbens and hippocampus [67, 120, 121]. Assessment of dopamine, glu‐
tamate, and GABA related receptors in the PFC would provide important information nec‐
essary for proper evaluation of receptors that could be contributing to the findings reported
in this paper and need to be further investigated. Compensatory mechanisms can be indica‐
tive of developmental functions that are influenced by the absence of the DRD4 and are im‐
portant to consider when evaluating glutamate function in the PFC of these knockouts.
2.10. Future directions in the neuropharmacology of ADHD
The data presented above in the SHR and DRD4-/- rodent models of ADHD provide evi‐
dence for dopaminergic and glutamatergic system dysfunction in the PFC. Likewise, it has
previously been demonstrated that in the striatum of both models, similar neurotransmitter
system dysfunction exists [52, 67]. The DRD4 knockout mouse has also been found to exhibit
decreased dopamine levels in the striatum [120]. These data in the DRD4-/- reveal that the D4
receptor is vital in the regulation of dopamine-glutamate interactions in the striatum and
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PFC. Recent pilot data from our lab (unpublished) reveal that in the SHR model of ADHD,
there exists increased resting glutamate levels in the striatum and PFC; however, further ex‐
perimentation is necessary to verify these results. Glutamate dysfunction in the SHR would
then create the possibility that targeting the dopamine-glutamate interaction in this model of
ADHD may prove useful as well.
These animal models grant us the ability to investigate neurotransmitter system regulation
in vivo, creating a more accurate depiction of the dysfunction in multiple subregions within
the PFC. Using these animals, we plan to use common ADHD treatments, such as MPH and
ATX, as well as unconventional treatments, such as memantine and deprenyl, to examine
the effects of these drugs on the dopamine and glutamate neuronal systems. Our ultimate
goal is to discover novel ways to treat ADHD with minimal side-effects and clear long-term
safety and efficacy. Avoiding the confounding side effect of abuse potential will be especial‐
ly advantageous given the difficulties this presents to prescribing stimulants. We believe
that targeting the interaction between the dopamine and glutamate systems will provide a
new avenue to achieve our goal.
As more and more research is beginning to implicate a dysfunctional glutamate system in
ADHD, it’s hard to ignore that glutamate may be playing some role in the pathophysiology
of ADHD. Although it is too early to know if pharmaceuticals that modulate glutamate will
be able to benefit ADHD without their own set of side-effects, it is still our hope that
through modification of these interactions, we will be able to better treat individuals with
ADHD and greatly improve their quality of life.
3. Conclusion
In this chapter, we have reviewed dopamine and glutamate neurotransmission, as well as
dopamine-glutamate interactions, specifically relating to ADHD. We have reviewed current
literature and have shown the effects of ADHD treatments on these neurotransmitters. We
have discussed and detailed two rodent models of ADHD as well as the techniques used to
highlight novel data revealing dopamine and glutamate dysfunction in these models of
ADHD. Finally, we’ve examined ways these data will enable the future neuropharmacology
of ADHD to move forward. Ultimately, our goal is to find novel therapies targeting dopa‐
mine-glutamate interactions to better treat ADHD in individuals of all ages.
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